NCT01803373View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of TMC207 Following Single-Dose Administrations of Two Pediatric Formulations in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
HealthyBiological Availability
Interventions
DRUG

Treatment A (reference)

One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

DRUG

Treatment B

Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

DRUG

Treatment C

5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Trial Locations (1)

Unknown

Groningen

All Listed Sponsors
lead

Janssen Infectious Diseases BVBA

INDUSTRY

NCT01803373 - A Study to Assess the Relative Bioavailability of TMC207 Following Single-Dose Administrations of Two Pediatric Formulations in Healthy Adult Participants | Biotech Hunter | Biotech Hunter